Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
Etrasimod shows moderate benefit over existing treatments for moderately to severely active ulcerative colitis, demonstrating effectiveness compared to placebo. However, it has not been directly compared to standard treatments, leading to some uncertainty in its relative efficacy.
Cost effectiveness
Etrasimod is suggested to have lower or similar costs compared to adalimumab and other advanced treatments, indicating a clear cost-effective profile under common thresholds.
Quality of life
The document does not provide specific data on HRQoL improvements associated with etrasimod, indicating minimal or mixed impact on quality of life without robust evidence from validated instruments.
Supporting Domains
Safety and Adverse Effects
The safety profile of etrasimod appears acceptable, with no significant adverse events reported that would undermine its use compared to existing therapies.
Comparator Selection
Etrasimod has not been directly compared to usual treatments in clinical trials, relying instead on indirect comparisons which introduce uncertainty regarding its relative effectiveness.
Patient Population and Subgroups
The trial population for etrasimod is representative of the intended patient population, covering those aged 16 and over with moderately to severely active ulcerative colitis.
Care Pathway Integration
Etrasimod can be integrated into existing treatment pathways with minor adjustments, as it is positioned as an additional option for patients who have not responded to conventional or biological treatments.
Resource Use and Cost Implications
The estimated annual cost of treatment is justifiable given the potential benefits, and the commercial arrangement suggests a manageable budget impact.
Evidence Quality and Robustness
The evidence base includes clinical trial data showing efficacy compared to placebo, although the lack of direct comparisons introduces some methodological concerns.
Uncertainty, Sensitivity, and Broader Impacts
There is notable uncertainty regarding the effectiveness of etrasimod compared to other treatments, particularly for patients who have previously received advanced treatment, which may limit its broader applicability.
